Brief: Seagen Says Adcetris Plus Novel Immunotherapy Combination Delivers 98% Overall Response Rate And 93% Complete Response Rate In Patients With Early-Stage Classical Hodgkin Lymphoma
13/06/2023 08:02
June 13 (Reuters) - Seagen Inc SGEN.O :
* SEAGEN ANNOUNCES ADCETRIS® (BRENTUXIMAB VEDOTIN) PLUS
NOVEL
IMMUNOTHERAPY COMBINATION DELIVERS 98% OVERALL RESPONSE RATE AND
93% COMPLETE RESPONSE RATE IN PATIENTS WITH EARLY-STAGE
CLASSICAL HODGKIN LYMPHOMA (CHL)
* SEAGEN -REGIMEN WELL-TOLERATED WITH FEWER THAN HALF OF
PATIENTS
DEVELOPING PRIMARILY LOW-GRADE PERIPHERAL NEUROPATHY,NO CASES OF
FEBRILE NEUTROPENIA
Source text for Eikon: ID:nBw4db33Pa
Further company coverage: SGEN.O
((Reuters.Briefs@thomsonreuters.com;))